3 ms·

Sputnik V vaccine Ad5 vector is replication competent

13 points by stefan_ 6y ago

gus_massa 6y ago
Note: Ad5 is used in the "second" dose, not in the "first" dose.
jhayward 6y ago
From Dr. Rasmussen’s thread it seems like this is most likely a manufacturing error rather than a design error. Still, it is pretty unforgivably incompetent to let such a mistake make it out the door.
nikolay 6y ago
If this was true, we would have known about it already from adverse effects. Looking at the Hungary's data [0], for example, it looks Sputnik V and Sinovac fared much better than rivals. This looks like the typical American stunt to reduce the distribution of the Russian and Chinese vaccines, and also to hurt the image of Russia or China like competent rivals. [0]: https://www.facebook.com/kormanyzat/posts/5439413329464676 https://www.facebook.com/kormanyzat/posts/5439413329464676
- joyeuse6701 6y ago
  If it’s true, at best the vaccine receivers would have experienced a cold or cold like symptoms beyond the norm. At worst they effectively received a placebo, based on Dr. Rasmussen’s comments. Any data from Russia/Hungary is suspect, at least at the same rate that the data is suspect from every country that’s had significant Covid.
  - nikolay 6y ago
    Based on what you're saying, Brazil's data should be questionable, too.
- rsynnott 6y ago
  You wouldn't necessarily expect severe adverse effects. But it's both not the framing the vaccine was tested in, and speaks to inconsistency of batches. I don't think anyone has suggested the Chinese adenovirus vaccine has similar issues?
baybal2 6y ago
Even if it is replication competent, simian adenovirus shouldn't be that much of a problem for a healthy young person
- gus_massa 6y ago
  IIUC, Ad5 is a human virus. See the discussion in https://blogs.sciencemag.org/pipeline/archives/2021/04/28/brazil-rejects-the-gamaleya-vaccine https://blogs.sciencemag.org/pipeline/archives/2021/04/28/br... Also, here in Argentina the persons that get the vaccine are mostly the ones in the risk group, like people with at least 75 years. (Most of the vaccinated people only got the first dose.)

13 points by stefan_ 6y ago

Note: Ad5 is used in the "second" dose, not in the "first" dose.

From Dr. Rasmussen’s thread it seems like this is most likely a manufacturing error rather than a design error. Still, it is pretty unforgivably incompetent to let such a mistake make it out the door.

nikolay 6y ago

If this was true, we would have known about it already from adverse effects. Looking at the Hungary's data [0], for example, it looks Sputnik V and Sinovac fared much better than rivals. This looks like the typical American stunt to reduce the distribution of the Russian and Chinese vaccines, and also to hurt the image of Russia or China like competent rivals. [0]: https://www.facebook.com/kormanyzat/posts/5439413329464676 https://www.facebook.com/kormanyzat/posts/5439413329464676

joyeuse6701 6y ago
If it’s true, at best the vaccine receivers would have experienced a cold or cold like symptoms beyond the norm. At worst they effectively received a placebo, based on Dr. Rasmussen’s comments. Any data from Russia/Hungary is suspect, at least at the same rate that the data is suspect from every country that’s had significant Covid.
- nikolay 6y ago
  Based on what you're saying, Brazil's data should be questionable, too.
rsynnott 6y ago
You wouldn't necessarily expect severe adverse effects. But it's both not the framing the vaccine was tested in, and speaks to inconsistency of batches. I don't think anyone has suggested the Chinese adenovirus vaccine has similar issues?

baybal2 6y ago

Even if it is replication competent, simian adenovirus shouldn't be that much of a problem for a healthy young person

gus_massa 6y ago
IIUC, Ad5 is a human virus. See the discussion in https://blogs.sciencemag.org/pipeline/archives/2021/04/28/brazil-rejects-the-gamaleya-vaccine https://blogs.sciencemag.org/pipeline/archives/2021/04/28/br... Also, here in Argentina the persons that get the vaccine are mostly the ones in the risk group, like people with at least 75 years. (Most of the vaccinated people only got the first dose.)